ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland– September30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Luigi Marro, as Chief Transformation Officer (CTO) and member of the company’s Executive Committee, effective October 1, 2021. Mr. Marro will lead the Company’s strategic Commercial Operational Readiness initiative.
“We are delighted to welcome Luigi to ObsEva’s executive team,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “Luigi’s comprehensive commercial experience in the reproductive health landscape, deep financial expertise and contributions as a consultant thus far, makes him an ideal fit. We are confident that his impressive track record will be invaluable as we continue to pursue regulatory approvals and advance toward commercialization of linzagolix for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids in pre-menopausal women.”
Mr. Marro added, “I am excited to be joining ObsEva at this critical juncture and look forward to working with the outstanding team to drive successful transformation outcomes as we prepare linzagolix for market launch in uterine fibroids, if approved.”
Luigi Marro is a pharmaceutical and biotech executive with over 20 years of experience. He has a background in finance, operations and has managed global businesses across multiple therapeutic areas from development stages through commercialization. Most recently, Mr. Marro founded his own consulting company to support biotech and pharmaceutical startups. Before this, Mr. Marro served as Chief Financial Officer at Finox Biotech, which launched the first biosimilar recombinant follicle stimulating hormone (r-FSH) product to market. Previously, Mr. Marro held leadership positions at Voisin Life Sciences Consulting SA as Chief Operating Officer and at Merck Serono as Senior Director Strategy Development and Business Performance. Prior to Serono’s acquisition by Merck, Mr. Marro held elevating strategic roles. Mr. Marro holds a university degree in Demographic and Economical Statistic Sciences from La Sapienza in Rome as well as a Master of Business Administration from Luiss Management school in Rome.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
+41 22 552 1550
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes27.10.2021 22:00:00 CEST | Press release
The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance®1) in patients with non-alcoholic steatohepatitis (NASH) and type 2 diabetes (T2D)The trial will be conducted in several sites in the United States and Europe with a treatment duration of 24 weeks, and a total enrollment target of 63 patients with T2D and non-cirrhotic NASHThe initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 Daix (France), Long Island City (New York, United States), October 27, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the design of a proof-of-concept Phase IIa co
Johnson & Johnson partially converts its convertible loan27.10.2021 19:03:46 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 27, 2021 Idorsia Ltd (SIX: IDIA) today announced that Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, notified Idorsia that it will convert a second tranche of the remaining principal amount of CHF 445 million convertible loan, such that CHF 110 million will be converted into 9.6 million shares of Idorsia. As a result of the conversion, Idorsia will issue 9’581’882 new shares and Idorsia share capital will increase from CHF 8’364’748.55 to CHF 8’843’842.65, divided into 176’876’853 Idorsia shares. As a result of conversion of the second tranche of the convertible loan, Cilag Holding AG will hold 5.7% of Idorsia’s issued share capital. Following conversion, the remaining principal amount of the convertible loan will be CHF 335 million, convertible into 29.1 million shares of Idorsia. Notes to the editor About the convertible loan On June 15, 2017, Cilag Holding AG (“Cilag”) provided a loan of CHF
AMG Advanced Metallurgical Group N.V. Reports Third Quarter 2021 Results27.10.2021 18:00:00 CEST | Press release
Coronavirus Update Active cases at AMG remain at a very low level. We continue to apply all safety measures at our disposal with the highest degree of attention in order to ensure our employees are working in the lowest risk environment possible. Strategic Highlights The construction of AMG Vanadium’s second spent catalyst recycling facility in Zanesville, Ohio, a $325 million investment and AMG’s largest capital project to date, is proceeding as planned. Commissioning starts in the first quarter of 2022 and the plant is forecast to achieve full run rate capacity in the fourth quarter of 2022.Spodumene 1+ will increase Brazil’s spodumene production by 40,000 tons. The project is currently in detailed engineering and commissioning is planned to start in the second quarter of 2023.AMG’s Supervisory Board approved the construction of the first module of a battery grade lithium hydroxide upgrader in Bitterfeld, Germany in its meeting on October 27, 2021. The total expenditure of $120 milli
The world’s first fully accessible art depot opens its doors in 10 days27.10.2021 16:36:25 CEST | Press release
Depot Boijmans Van Beuningen in Rotterdam Rotterdam, Oct. 27, 2021 (GLOBE NEWSWIRE) -- The world’s first fully accessible art depot opens its doors in 10 days Depot Boijmans Van Beuningen is set to open its doors in 10 days – on 6 November 2021 – making the entire internationally renowned art collection of Museum Boijmans Van Beuningen accessible to the public. Museums around the world usually display just 6 to 10 percent of their collections; the rest lies in storage. Depot Boijmans Van Beuningen breaks with this hidden tradition and makes all the invisible artworks visible – a world first. In the iconic, mirrored art depot designed by MVRDV the museum’s 151,000 artefacts are placed at the heart of the city. The depot’s ovoid shape makes it a building that is open in every direction. The bowl-like form means that the footprint is small and the rooftop area as expansive as possible. The fully mirrored edifice consists of 6,609 square metres of glass, divided into 1,664 mirror panels, w
Workday presenterar en djupare digital upplevelse för anställda med Workday Everywhere27.10.2021 16:24:43 CEST | Pressemelding
Obegränsad upplevelse etablerar Workday inom populära arbetsområden och företagsappar för att hjälpa anställda att hålla sig engagerade, produktiva och uppkopplade. STOCKHOLM, Sweden, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Workday, Inc. (NASDAQ: WDAY), en ledande leverantör inom molnlösningar för företag inom ekonomi och HR, tillkännagav idag lanseringen av Workday Everywhere, paketerade anslutningar som tar uppgifter och insikter från Workday direkt till digitala arbetsmiljöer för att hjälpa organisationer att förbättra anställdas upplevelser. Med Workday Everywhere kan anställda snabbt få tillgång till Workday i sitt arbetsflöde utan att växla mellan olika applikationer. Arbetsgivare kan använda Workday Everywhere för att leverera en enkel och uppkopplad upplevelse som förbättrar medarbetarnas produktivitet och engagemang. Workday Everywhere är det senaste erbjudandet från Workday för medarbetare upplevelser och stödjer en pågående satsning för att öka engagemanget med en öppen och frikti
Aspo’s financial reporting in 202227.10.2021 12:00:00 CEST | Press release
Aspo Plc Stock Exchange Release October 27, 2021 at 1 p.m. Aspo’s financial reporting in 2022 In 2022, Aspo Plc will publish its financial statement release, half year financial report and two interim reports as follows: - financial statement release for 2021 on Wednesday, February 16, 2022 - interim report for January-March on Wednesday, May 4, 2022 - half year financial report for January-June on Wednesday, August 10, 2022 - interim report for January-September on Wednesday, November 2, 2022 The Financial Statements and Sustainability Report 2021 will be published on the company’s website during week 10. Aspo’s Annual Shareholders’ Meeting is scheduled for Wednesday, April 6, 2022, in Helsinki, Finland. The Board of Directors will give a separate notice of the Annual Shareholders’ Meeting later. Possible requests from shareholders to include matters on the agenda of Aspo’s 2021 Annual Shareholders’ Meeting shall be sent to Aspo’s Board of Directors not later than February 9, 2022. Th
Correction: RESULT RIKSBANK PURCHASES OF CORPORATE BONDS27.10.2021 11:35:12 CEST | Press release
AuctionResult of auctionAuction date2021-10-27NameHeimstaden Bostad ABIsinXS2259781230Coupon, spread1.368Maturity2025-02-25Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln-Volume bought, SEK mln-Number of bids-Number of accepted bids-Average yield, DM-Lowest accepted yield, DM-Highest yield, DM-Accepted at lowest yield, %- AuctionResult of auctionAuction date2021-10-27NameCastellum ABIsinSE0012675916Coupon, spread1.545Maturity2025-11-27Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln6Volume bought, SEK mln6Number of bids1Number of accepted bids1Average yield, DM1.400%Lowest accepted yield, DM1.400%Highest yield, DM1.400%Accepted at lowest yield, %100.00 AuctionResult of auctionAuction date2021-10-27NameCastellum ABIsinSE0011062827Coupon, spread1.650Maturity2023-05-17Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln-Volume bought, SEK mln-Number of bids-Number of accepted bids-Average yield, DM-Lowest accepted yield, DM-Highest yield, DM-Accepted at lowest yield,